Michael Colucciello MD       

Medical and Surgical Retina and Macula Consultant                          
Macula.us Home
Michael Colucciello MD
Contact Information
Age-Related Macular Degeneration
AMD Testing
Wet AMD treatment: Avastin
Wet AMD treatment: Lucentis
Wet AMD treatment: Eylea
Wet AMD treatment: Visudyne PDT
Diabetic Retinopathy
Retinal Venous Occlusive Disease
Macular Hole
Macular Pucker
Macular Edema
Central Serous Chorioretinopathy
Retinal Tear
Retinal Detachment
Retinal Arterial disease
Controversies in Care Articles
Michael Colucciello MD Retina Articles
Michael Colucciello MD: Curriculum Vitae
New Custom 1

Ranibizumab (trade name Lucentis) is a monoclonal antibody fragment derived from the same parent mouse antibody as Bevacizumab (Avastin). It is much smaller than the parent molecule Avastin; it has been manufactured to provide stronger binding to Vascular Endothelial Growth Factor (VEGF). 

Ranibizumab binds to and inhibits a number of subtypes of VEGF.  VEGF triggers the growth of new vessels, which may leak blood and fluid into the retina. These leaky blood vessels result in the wet type of AMD.


Prior to Lucentis intravitreal treatment (left), subretinal fluid (black area under retina profile) is present.

One month after treatment (right), subretinal fluid has resorbed and vision has improved.